John N. Papadopoulos, M.D.
Department of Urology, Division of Surgery
Present Title & Affiliation
Primary Appointment
Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Professor, Urology, The University of Texas MD Anderson Cancer Center
Education & Training
Degree-Granting Education
| 2002 | Texas Tech University School of Medicine, Lubbock, Texas, US, MD |
| 1997 | University of Texas, Austin, Texas, US, BA in Business Administration in Finance |
Postgraduate Training
| 2007-2009 | Clinical Fellowship, Urology Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2007-2008 | Research Fellowship, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2004-2007 | Clinical Residency, General, University of Wisconsin Hospital and Clinics, Madison, Wisconsin |
| 2003-2004 | Clinical Internship, General Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin |
| 2001-2001 | Medical Student, Urology Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1994-1994 | College Research Program, Research, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Licenses & Certifications
| 2012 | Texas Medical Board |
| 2011 | American Board of Urology |
Experience & Service
Faculty Academic Appointments
Associate Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024
Assistant Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2018
Other Professional Positions
Urology Resident Representative, University of Wisconsin House Staff Association, Madison, WI, 2004 - 2007
Extramural Institutional Committee Activities
Member, Northwell- GAP Assessment Team, The University of Texas MD Anderson Cancer Center, 2017 - 2018
Member, Summit Medical Group Relationship Team, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2015 - 2021
Representative, MD Anderson Cooper Relationship Team, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2014 - 2021
Honors & Awards
| 2007 | Second Prize Abstract Presentation, Wisconsin Urological Society |
| 2005 | Gerald P. Murphy Scholar, American Urological Association |
| 2004 | First Prize Abstract Presentation, Wisconsin Urological Society |
| 2001 - 2002 | Student Senate Scholarship, Texas Tech University Health Sciences |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2015. Postoperative Telerounding Using Mobile Technology: Is This Feasible and Who Benefits?. Conference. Postoperative Telerounding Using Mobile Technology: Is This Feasible and Who Benefits?. Houston, TX, US.
- 2013. Reduce Your Cancer Risks for Men. Conference. Reduce Your Cancer Risks for Men. Houston, TX, US.
- 2013. Testicular Cancer Awareness. Conference. Testicular Cancer Awareness. Houston, TX, US.
Regional Presentations
- 2023. University of Texas Christopher G. Wood Advances in Urologic Oncology Symposium. Conference. University of Texas Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, TX, US.
- 2016. Active Surveillance Monitoring: How to Choose From Repeat Biopsy, Biomarkers, and Imaging. Conference. Active Surveillance Monitoring: How to Choose From Repeat Biopsy, Biomarkers, and Imaging, TX, US.
- 2015. What is the Best Therapy for high risk stage one testicular cancer?. Conference. What is the Best Therapy for high risk stage one testicular cancer?, TX, US.
- 2015. Optimizing Post-Operative Care After Bladder Removal Surgery: Can we do Better?. Conference. Optimizing Post-Operative Care After Bladder Removal Surgery: Can we do Better?, TX, US.
- 2014. What is the Best Therapy for cT1c Gleason 7 Prostate Cancer?. Conference. What is the Best Therapy for cT1c Gleason 7 Prostate Cancer?, TX, US.
- 2014. What's New in Imaging, Medicine and Therapies. Conference. What's New in Imaging, Medicine and Therapies, TX, US.
- 2012. PSA Screening for Prostate Cancer. Conference. PSA Screening for Prostate Cancer. Sugar Land, TX, US.
- 2012. Protect your Prostate. Get the Facts. Conference. Protect your Prostate. Get the Facts, US.
- 2012. Cancer Prevention. Conference. Cancer Prevention. Sugar Land, TX, US.
- 2011. Establishing a urologic oncology program. Conference. Establishing a urologic oncology program. Bethesda, MD, US.
National Presentations
- 2011. Establishing a Urologic Oncology Research Program. Conference. Establishing a Urologic Oncology Research Program, US.
- 2008. The Role of Platelet-derived growth Factor in Prostate CA Development and Progression Depends on Organ Site of Involvement in an Orthotopic Mouse Model. Conference. The Role of Platelet-derived growth Factor in Prostate CA Development and Progression Depends on Organ Site of Involvement in an Orthotopic Mouse Model. San Diego, CA, US.
- 2008. The Mitotic Spinkle Apparatus Inhibitor AZD4877 Holds Promise as a Novel Therapeutic Option Against Human Bladder Cancer. Conference. The Mitotic Spinkle Apparatus Inhibitor AZD4877 Holds Promise as a Novel Therapeutic Option Against Human Bladder Cancer, US.
- 2007. Five Atrial Thrombectomies in Ten Months: What We Have Learned in the Context of New Techinques and Therapies for Renal Cell Carcinoma. Conference. Five Atrial Thrombectomies in Ten Months: What We Have Learned in the Context of New Techinques and Therapies for Renal Cell Carcinoma. Madison, WV, US.
- 2005. Medical Compliance Decreases Urologic Intervention in Cystinuric Patients. Conference. Medical Compliance Decreases Urologic Intervention in Cystinuric Patients. Chicago, IL, US.
- 2004. Case-matched Comparisons of 220f EMSE and 140f EMSE on the DoLi-S Lithotriptor in the Treatment of Renal Calculi. Conference. Case-matched Comparisons of 220f EMSE and 140f EMSE on the DoLi-S Lithotriptor in the Treatment of Renal Calculi. Madison, WI, US.
Selected Publications
Peer-Reviewed Articles
- Hahn, AW, Manyam, GC, Chapin, BF, Zhang, M, Yu, Y, Pettaway, CA, Chery, LJ, Pisters, LL, Ward, JF, Gregg, JR, Papadopoulos, JN, Kamat, A, Lozano, M, Hoang, A, Broom, BM, Wang, X, Huff, C, Logothetis, CJ, Troncoso, P, Pilie, PG, Davis, JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU International 134(3):449-458, 2024. e-Pub 2024. PMID: 38837608.
- Ozambela, M, McCormick, B, Rudzinski, JK, Pieretti, AC, González, GM, Meissner, M, Papadopoulos, JN, Adibi, M, Matin, S, Dahmen, AS, Spiess, PE, Pettaway, CA. Robotic or open superficial inguinal lymph node dissection as staging procedures for clinically node negative high risk penile cancer. Urologic Oncology: Seminars and Original Investigations 42(4):120.e1-120.e9, 2024. e-Pub 2024. PMID: 38388244.
- Gregg, JR, Magill, RG, Fang, AM, Chapin, BF, Davis, JW, Adibi, M, Chery, LJ, Papadopoulos, JN, Pettaway, CA, Pisters, LL, Ward, J, Hahn, AW, Daniel-MacDougall, CR, Bhaskaran, J, Zhu, K, Guerrero, M, Zhang, M, Troncoso, P. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations 42(4):116.e1-116.e7, 2024. e-Pub 2024. PMID: 38262868.
- Westerman, ME, Bree, KK, Msaouel, P, Kukreja, JB, Mantaring, C, Rukundo, I, Gonzalez, MG, Gregg, JR, Casteel, KN, Matin, S, Lafleur, AD, Best, RN, Crump, LD, Cunningham, JM, Saucedo, MA, Valle, DD, Varghese, R, Adibi, M, Chapin, BF, Chery, LJ, Davis, JW, Dinney, CP, Graber, WJ, Kamat, A, Karam, JA, Navai, N, Papadopoulos, JN, Pettaway, CA, Pisters, LL, Smith III, T, Ward, JF, Westney, OL, Wood, CG. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis. Journal of Urology 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
- Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol 40(10):454.e17-454.e23, 2022. e-Pub 2022. PMID: 35961847.
- Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. Eur J Cancer 157:259-267, 2021. e-Pub 2021. PMID: 34536949.
- Kokorovic A, Duplisea J, Qiao W, McCormick B, Adibi M, Papadopoulos J, Ramirez G, Rao P, Tamboli P, Pettaway C. Oncologic outcomes and subsequent treatment following organ sparing surgery for penile carcinoma: The University of Texas M.D. Anderson Cancer Center Experience. Urol Oncol 39(5):302.e19-302.e27, 2021. e-Pub 2021. PMID: 33612354.
- Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
- Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol 36(12):2027-2034, 2018. e-Pub 2018. PMID: 29804202.
- Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol 31(9):946-953, 2017. e-Pub 2017. PMID: 28731777.
- Hassid VJ, Papadopoulos JN. Penile Squamous Cell Carcinoma Masquerading as Giant Condyloma. Plast Reconstr Surg Glob Open 5(3):e1269, 2017. e-Pub 2017. PMID: 28458981.
- Katz MH, Slack R, Bruno M, McMillan J, Fleming JB, Lee JE, Bednarski B, Papadopoulos J, Matin SF. Outpatient virtual clinical encounters after complex surgery for cancer: a prospective pilot study of "TeleDischarge". J Surg Res 202(1):196-203, 2016. e-Pub 2016. PMID: 27083967.
- Lee HJ, Yu HK, Papadopoulos JN, Kim SW, He J, Park YK, Yoon Y, Kim JS, Kim SJ. Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model. Neoplasia 14(4):335-43, 2012. e-Pub 2012. PMID: 22577348.
- Kim SW, Kim JS, Papadopoulos J, Choi HJ, He J, Maya M, Langley RR, Fan D, Fidler IJ, Kim SJ. Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol 11(7):862-72, 2011. e-Pub 2011. PMID: 21251905.
Invited Articles
- Kim SJ, Kim JS, Papadopoulos J, Wook Kim S, Maya M, Zhang F, He J, Fan D, Langley R, Fidler IJ. Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol 174(5):1972-80, 2009. e-Pub 2009. PMID: 19349357.
- Kaplon D, Jarrard DF, Papadopoulos JN. Urothelial Tumors of the Renal Pelvis and Ureters. eMedicine, 2009. e-Pub 2009.
- Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 181(1):81-7; discussion 87, 2009. e-Pub 2009. PMID: 19012911.
- Shaw A, Papadopoulos J, Johnson C, Bushman W. Isolation and characterization of an immortalized mouse urogenital sinus mesenchyme cell line. Prostate 66(13):1347-58, 2006. e-Pub 2006. PMID: 16752376.
Abstracts
- Wilson N, Alhalabi O, Hasanov E, Xiao L, Papadopoulos J, Campbell M, Shah A, Gao J, Corn P, Aparicio A, Wang J, Czerniak B, Guo C, Logothetis C, Li J, Choi S, Tang C, Tannir N, Siefker-Radtke A. 241 Immune checkpoint blockade (ICB) in brain metastases (BM) from advanced small cell urothelial cancer (aSCUC). J for Immunotherapy of Cancer(A259), 2021. e-Pub 2021.
- Hensley PJ, Miest T, Adibi M, Campbell M, Shah A, Cherry L, Papadopoulos J, Siefker-Radtke A, Gao J, Guo C, Czerniak B, Navai N, Kamat A, Dinney, CP, Matin S. GFR fluctuation induced by neoadjuvant chemotherapy correlates with pathologic stage of upper tract urothelial carcinoma. European Urology 79S(S1090), 2021. e-Pub 2021.
- Zurita AJ, Slack R, Troncoso P, Chapin BF, Harris H, Pisters LL, Araujo JC, Pettaway CA, Aparicio A, Tu SM, Papadopoulos JN, Wang J, Logothetis C, Pagliaro LC, Davis JW. Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis, 2019 ASCO Annual Meeting. American Society of Clinical Oncology, 2019. e-Pub 2019.
- Hassid VJ, Papadopoulos JN. Penile Squamous Cell CarcinomaMasquerading as Giant Condyloma. Plast Reconstr Surg Glob Open 5(3):1269PMC, 2017. e-Pub 2017. PMID: 28458981.
- Davis JW, JFrd W, Pettaway CA, Wang X, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease Re-classification Risk with Stringent Criteria and Frequent Monitoring in Men with Favourable-risk Prostate Cancer Undergoing Active Surveillance. BJU International 118(1):68-76, 2016. e-Pub 2016. PMID: 26059275.
- Davis JW, JFrd W, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos, JN, Achim M, Hofman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. Journal of Clinical Oncology, 2015. e-Pub 2015.
- Davis JW, Achim MD, Ward JF, MD, FACS, Pettaway CA, MD, Chapin BF, Wang MD, MS, Kuban DA, Frank MD, MD, Lee AL, MD, MPD, Pisters LL, MD, Matin SF, MD, FACS, Shah JB, MD, Karam JA, MD, Papadopoulos JN, MD, Hoffman KE, MHSC MD, MPH, Pugh TJ, MD. Active Surveillance in Men with Phenotypically Heterogeneous Early Stage Prostate Cancer, 2014. e-Pub 2014.
- Magill RG, Davis JW, Pettaway C, Pisters L, Ward JF, Chapin BF, Papadopolous J, Adibi M, Chery L, Guerrero M, Zhang M, Troncoso P, Gregg JR. Association of Body Mass Index with Tumor Zonal Origin and Pathologic Features at Radical Prostatectomy. SUO - Society of Urologic Oncology.
Patient Reviews
CV information above last modified July 22, 2026